Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INKT NASDAQ:JBIO NASDAQ:RNAC NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINKTMiNK Therapeutics$14.27-0.9%$16.88$4.56▼$76.00$64.50M0.33373,751 shs28,693 shsJBIOJade Biosciences$7.07-8.2%$8.09$6.57▼$105.00$230.67M1.04156,525 shs130,871 shsRNACCartesian Therapeutics$9.79+1.1%$11.58$8.46▼$26.50$254.54M0.3978,802 shs87,415 shsTNXPTonix Pharmaceuticals$27.75-3.0%$39.72$6.76▼$130.00$243.26M1.861.38 million shs1.11 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINKTMiNK Therapeutics0.00%-2.70%-3.42%+95.65%+85.69%JBIOJade Biosciences0.00%-0.90%+4.62%+10.16%+769,999,900.00%RNACCartesian Therapeutics0.00%-9.02%-14.56%-6.20%-42.21%TNXPTonix Pharmaceuticals0.00%+7.80%-44.38%-22.61%+82.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINKTMiNK Therapeutics$14.27-0.9%$16.88$4.56▼$76.00$64.50M0.33373,751 shs28,693 shsJBIOJade Biosciences$7.07-8.2%$8.09$6.57▼$105.00$230.67M1.04156,525 shs130,871 shsRNACCartesian Therapeutics$9.79+1.1%$11.58$8.46▼$26.50$254.54M0.3978,802 shs87,415 shsTNXPTonix Pharmaceuticals$27.75-3.0%$39.72$6.76▼$130.00$243.26M1.861.38 million shs1.11 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINKTMiNK Therapeutics0.00%-2.70%-3.42%+95.65%+85.69%JBIOJade Biosciences0.00%-0.90%+4.62%+10.16%+769,999,900.00%RNACCartesian Therapeutics0.00%-9.02%-14.56%-6.20%-42.21%TNXPTonix Pharmaceuticals0.00%+7.80%-44.38%-22.61%+82.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINKTMiNK Therapeutics 2.60Moderate Buy$37.50162.79% UpsideJBIOJade Biosciences 3.00Buy$16.00126.31% UpsideRNACCartesian Therapeutics 2.80Moderate Buy$40.00308.58% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.00152.25% UpsideCurrent Analyst Ratings BreakdownLatest INKT, RNAC, TNXP, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $18.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ARNACCartesian Therapeutics$38.91M6.54N/AN/A($0.27) per share-36.26TNXPTonix Pharmaceuticals$9.83M24.74N/AN/A$31.82 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)JBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ARNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)Latest INKT, RNAC, TNXP, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 million8/7/2025Q2 2025RNACCartesian Therapeutics-$0.76$0.50+$1.26$0.50$0.77 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINKTMiNK TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINKTMiNK TherapeuticsN/A0.150.15JBIOJade BiosciencesN/A10.3110.31RNACCartesian TherapeuticsN/A13.3313.33TNXPTonix PharmaceuticalsN/A7.537.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINKTMiNK Therapeutics2.87%JBIOJade BiosciencesN/ARNACCartesian Therapeutics86.95%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipINKTMiNK Therapeutics22.48%JBIOJade Biosciences24.90%RNACCartesian Therapeutics60.30%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataJBIOJade Biosciences2032.63 million24.50 millionN/ARNACCartesian Therapeutics6426.00 million10.32 millionOptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableINKT, RNAC, TNXP, and JBIO HeadlinesRecent News About These CompaniesTonix Pharmaceuticals presents clinical data on Tonmya at PAINWEEKSeptember 9, 2025 | msn.comTonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025September 8, 2025 | globenewswire.comThree new option listings and one option delisting on September 4thSeptember 4, 2025 | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Should You Sell?September 4, 2025 | marketbeat.comTonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025August 28, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Time to Sell?August 28, 2025 | marketbeat.comCarolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) StockAugust 22, 2025 | insidertrades.comSA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXPAugust 20, 2025 | msn.comTonix Pharma Announces FDA Approval of TonmyaAugust 19, 2025 | msn.comTonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)August 19, 2025 | seekingalpha.comTonix Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comFDA Approves New Fibromyalgia Drug, But Tonix Shares SlideAugust 18, 2025 | msn.comTonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 YearsAugust 18, 2025 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA ApprovalAugust 18, 2025 | gurufocus.comFDA Approves New Fibromyalgia Drug, Tonix Shares ClimbAugust 18, 2025 | msn.comThis Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’August 18, 2025 | msn.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLCAugust 18, 2025 | marketbeat.comNoble Financial Has Pessimistic Outlook of TNXP Q3 EarningsAugust 17, 2025 | marketbeat.comFDA approves first new fibromyalgia treatment in over 15 yearsAugust 16, 2025 | thepharmaletter.comTTonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comTonix Secures Fibromyalgia Approval - What Investors Should KnowAugust 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, RNAC, TNXP, and JBIO Company DescriptionsMiNK Therapeutics NASDAQ:INKT$14.27 -0.13 (-0.90%) Closing price 04:00 PM EasternExtended Trading$14.22 -0.04 (-0.32%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Jade Biosciences NASDAQ:JBIO$7.07 -0.63 (-8.18%) As of 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$9.79 +0.11 (+1.14%) Closing price 04:00 PM EasternExtended Trading$9.82 +0.04 (+0.36%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Tonix Pharmaceuticals NASDAQ:TNXP$27.75 -0.86 (-3.01%) Closing price 04:00 PM EasternExtended Trading$27.72 -0.02 (-0.09%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
